Karyopharm Therapeutics | KPTI - Pasivo Circulante





Pasivo Circulante Cambio Fecha
AbbVie USD 43.29B 3.9B 2025-12
Abbott USD 18.38B 1.88B 2026-03
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Incyte USD 1.49B 25.52M 2026-03
J&J USD 57.72B 3.59B 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
MacroGenics USD 43.11M 1.36M 2025-12
Merck USD 26.94B 1.38B 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Novartis USD 31.37B 4.1B 2026-03
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 34.35B 2.64B 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Takeda JPY 2.61T 470.53B 2025-12
Tectonic Therapeutic USD 9.67M 293K 2025-12
TG Therapeutics USD 153.76M 3.05M 2025-12
Ultragenyx Pharmaceutical USD 384M 43.98M 2025-12
Xencor USD 95.91M 9.42M 2025-12